???global.info.a_carregar???
Ana Martins da Silva is Consultant in Neurology at Oporto University Hospital Center (CHUP) leading the Neuroimmunology Clinic (Neurosciences Department). Is a member of the Clinical Immunology Unit and the Corino de Andrade Unit at CHUP. She is an Auxiliary Professor of Neurology at Abel Salazar Institute of Biomedical Sciences (ICBAS/Porto University) and a member of the UMIB's Autoimmunity & Neuroscience Research Group. Since 2010 is a Consultant of the Portuguese Directorate-General of Health (DGS). She is a National Delegate to the Medical and Scientific Board of the Multiple Sclerosis International Federation (MSIF). She is the principal, co-investigator and national coordinator of diverse clinical trials (phase 1, 2, 3, and 4) and principal investigator in multidisciplinary studies (involving genetics and neuropsychology) in the areas of Multiple Sclerosis and Familial Amyloid Polyneuropathy (hereditary ATTR amyloidosis).
Ler resumo completo ↓
Identificação

Identificação pessoal

Nome completo
Ana Alexandra Duarte Martins da Silva

Nomes de citação

  • Silva, Ana
  • Ana Martins Silva

Identificadores de autor

Ciência ID
1116-6606-5CF5
ORCID iD
0000-0002-1409-0831

Endereços de correio eletrónico

  • anamartins.neurologia@chporto.min-saude.pt (Profissional)

Moradas

  • Centro Hospitalar Universitario do Porto - Hospital de Santo António, Largo Abel Salazar, 441, Porto, Porto, Portugal (Profissional)

Domínios de atuação

  • Ciências Médicas e da Saúde - Medicina Clínica - Neurologia Clínica

Idiomas

Idioma Conversação Leitura Escrita Compreensão Peer-review
Português Utilizador proficiente (C1) Utilizador proficiente (C1) Utilizador proficiente (C1) Utilizador proficiente (C1)
Inglês Utilizador independente (B2) Utilizador proficiente (C1) Utilizador proficiente (C1) Utilizador proficiente (C1)
Francês Utilizador independente (B1) Utilizador proficiente (C1) Utilizador elementar (A1) Utilizador independente (B1)
Italiano Utilizador independente (B1) Utilizador independente (B1) Utilizador independente (B1)
Formação
Grau Classificação
2016/09 - 2016/12
Concluído
 Management in health organizations (Outros)
AESE Business School, Portugal
2014/06
Concluído
 Ciências Biomédicas (Doutoramento)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
"Funcionamento cognitivo em doentes com esclerose múltipla - estudo numa população portuguesa" (TESE/DISSERTAÇÃO)
 Aprovado com distinção
2003/10/01 - 2004/06/30
Concluído
 Neurology (Outros)
San Raffaelle Hospital, Itália
2004
Concluído
 Neurology (Diploma de especialização)
Centro Hospitalar Universitário do Porto EPE, Portugal
1996
Concluído
 Medicina (Licenciatura)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
 16
Percurso profissional

Docência no Ensino Superior

Categoria Profissional
Instituição de acolhimento 		Empregador
2014 - Atual Professor Auxiliar Convidado (Docente Universitário) Universidade do Porto, Portugal

Cargos e Funções

Categoria Profissional
Instituição de acolhimento 		Empregador
2014 - Atual Neurology Consultant Centro Hospitalar Universitário do Porto EPE, Portugal
Centro Hospitalar Universitário do Porto EPE, Portugal
2014 - Atual Member of Unit for Multidisciplinary Research in Biomedicine Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2009 - Atual Responsible for the Neuroimmunology Group Centro Hospitalar Universitário do Porto EPE, Portugal
2004 - Atual Member of Unit of Clinical Immunology Centro Hospitalar Universitário do Porto EPE, Portugal
2004 - Atual Member of Unit Corino de Andrade Centro Hospitalar Universitário do Porto EPE, Portugal

Outros

Categoria Profissional
Instituição de acolhimento 		Empregador
1999/01 - 2004/03 Neurologist Centro Hospitalar Universitário do Porto EPE, Portugal
Projetos

Bolsa

Designação Financiadores
2021 - Atual Covid-19 and neuroimmunological diseases study (cns-19): a retrospective non-interventional study for the evaluation of signs, symptoms and clinical course of sars-cov-2 infection in patients with neuroimmune
098-defi-101-ce
Investigador responsável
Centro Hospitalar Universitário do Porto EPE, Portugal
Em curso
2021 - Atual Cadeias leves livres Kappa no diagnóstico da esclerose múltipla
008-DEFI/008
Investigador responsável
Centro Hospitalar Universitário do Porto EPE, Portugal
Em curso
2021 - Atual The role of dysbiosis in immune cell dysfunction and disease exacerbation in two model autoimmune diseases
177-DEFI/178
Investigador responsável
Centro Hospitalar Universitário do Porto EPE, Portugal
Em curso
2020 - Atual MuSC-19: Multiple Sclerosis and Covid-19
169-DEFI/170-CE
Investigador responsável
Centro Hospitalar Universitário do Porto EPE, Portugal
Em curso
2019 - Atual A validação clínica de um teste olfativo na esclerose múltipla
184-19 (150-defi/156-ces)
Investigador responsável
Em curso
2016 - Atual Genetic and epigenetic biomarkers of disease progression in multiple sclerosis portuguese patients
2016.057
Investigador responsável
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
Em curso

Projeto

Designação Financiadores
2023/03/01 - 2026/02/28 O labirinto genético da Polineuropatia Amiloidótica Familiar ATTRV30M: uma abordagem genómica
10.54499/2022.01656.PTDC
2022.01656.PTDC
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal

Universidade do Porto Instituto de Investigação e Inovação em Saúde, Portugal
Fundação para a Ciência e a Tecnologia
Em curso
2010/05/01 - 2013/10/31 Variabilidade fenotípica e genes modificadores na Polineuropatia Amiloidótica Familiar PAF ATTRV30M
PTDC/SAU-GMG/100240/2008
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal

Universidade do Porto Instituto de Biologia Molecular e Celular, Portugal

Centro Hospitalar Universitário de Santo António, Portugal
Fundação para a Ciência e a Tecnologia
Concluído

Outro

Designação Financiadores
2020 - Atual Doença desmielinizante inaugural em período de pandemia de SARS-COV-2
2020.216
Investigador responsável
Centro Hospitalar Universitário do Porto EPE, Portugal
2019 - Atual O papel da disbiose intestinal nos surtos de doentes com esclerose múltipla
102-19 (083-defi/ 087-ces)
Investigador responsável
Centro Hospitalar Universitário do Porto EPE, Portugal
Em curso
2018 - Atual Impato do envelhecimento imunológico no desenvolvimento da esclerose múltipla
2018.113 (098 defi/ 097 ces)
Investigador responsável
2017 - Atual Doenças do espetro da neuromielite óptica em portugal (NMOSD) - registo multicêntrico
2017.151
Investigador responsável
2016 - Atual Reabilitação cognitiva - estudo clínico de intervenção: "multiple sclerosis rehabilitation protocol"
2016.068
Investigador responsável
Em curso
Produções

Publicações

Artigo em revista
  1. Ernestina Santos; João Moura; Raquel Samões; Ana Paula Sousa; Teresa Mendonça; Pedro Abreu; Joana Guimarães; et al. "Late onset neuromyelitis optica spectrum disorders (LONMOSD) from a nationwide Portuguese study: Anti-AQP4 positive, anti-MOG positive and seronegative subgroups". Multiple Sclerosis and Related Disorders (2022): http://dx.doi.org/10.1016/j.msard.2022.103845.
    10.1016/j.msard.2022.103845
  2. Costa, Diogo; Sardoeira, Ana; Carneiro, Paula; Neves, Esmeralda; Santos, Ernestina; da Silva, Ana Martins; Samões, Raquel. "Autoimmune encephalitis: suspicion in clinical practice and mimics". Journal of Neuroimmunology 365 (2022): 577824. http://dx.doi.org/10.1016/j.jneuroim.2022.577824.
    10.1016/j.jneuroim.2022.577824
  3. Alves Martins, Dulce; Lopes, Joana; Martins da Silva, Ana; Morais, Cátia Iracema; Vasconcelos, Júlia; Lima, Ivete; Carneiro, Carolina; Neves, Esmeralda. "Kappa free light chains: Diagnostic performance in multiple sclerosis and utility in a clinical laboratory". Clinica Chimica Acta 528 (2022): 56-64. http://dx.doi.org/10.1016/j.cca.2022.01.017.
    10.1016/j.cca.2022.01.017
  4. Martins, Cecília; Moura, João; Figueiroa, Sónia; Garrido, Cristina; Martins, Joana; Samões, Raquel; Guimarães, Joana; et al. "Pediatric neuromyelitis optica spectrum disorders in Portugal: A multicentre retrospective study". Multiple Sclerosis and Related Disorders 59 (2022): 103531. http://dx.doi.org/10.1016/j.msard.2022.103531.
    10.1016/j.msard.2022.103531
  5. Cavaco, Sara; Ferreira, Inês; Moreira, Inês; Santos, Ernestina; Samões, Raquel; Sousa, Ana Paula; Pinheiro, Joaquim; Teixeira-Pinto, Armando; Martins da Silva, Ana. "Cognitive dysfunction and mortality in multiple sclerosis: Long-term retrospective review". Multiple Sclerosis Journal (2021): 135245852110665. http://dx.doi.org/10.1177/13524585211066598.
    10.1177/13524585211066598
  6. Ana Martins Silva. "Neuromyelitis optica spectrum disorders: A nationwide Portuguese clinical epidemiological study". Multiple Sclerosis and Related Disorders 56 (2021): 103258-103258. http://dx.doi.org/10.1016/j.msard.2021.103258.
    10.1016/j.msard.2021.103258
  7. Ana Martins Silva. "Graves’ disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis". Endocrine Regulations 55 3 (2021): 169-173. http://dx.doi.org/10.2478/enr-2021-0018.
    10.2478/enr-2021-0018
  8. Videira, Gonçalo; Pereira, Diogo; Mota Dória, Hugo; Sousa, Ana Paula; Coelho, Teresa; Martins da Silva, Ana. "Myelopathy in hereditary ATTR Val30Met amyloidosis patients". Amyloid (2021): 1-2. http://dx.doi.org/10.1080/13506129.2021.1927696.
    10.1080/13506129.2021.1927696
  9. Nicolas Collongues; Cecilia Alves Do Rego; Bertrand Bourre; Damien Biotti; Romain Marignier; Ana Martins da Silva; Ernestina Santos; et al. "Pregnancy in Patients With AQP4-Ab, MOG-Ab, or Double-Negative Neuromyelitis Optica Disorder". Neurology 96 15 (2021): e2006-e2015. https://doi.org/10.1212/WNL.0000000000011744.
    10.1212/WNL.0000000000011744
  10. Ferreira, Ana Marta; Leal, Bárbara; Ferreira, Inês; Brás, Sandra; Moreira, Inês; Samões, Raquel; Sousa, Ana Paula; et al. "Depression and Anxiety in Multiple Sclerosis Patients: the role of genetic variability of Interleukin 1ß". Multiple Sclerosis and Related Disorders (2021): 102982. http://dx.doi.org/10.1016/j.msard.2021.102982.
    10.1016/j.msard.2021.102982
  11. Lopes, Ana M; Pereira, Josué; Ribeiro, Isabel; Martins da Silva, Ana; Queiroga, Henrique; Amaral, Cláudia. "Pituitary metastasis unveiling a lung adenocarcinoma". Endocrinology, Diabetes & Metabolism Case Reports 2021 (2021): http://dx.doi.org/10.1530/edm-20-0211.
    10.1530/edm-20-0211
  12. Nicolas Collongues; Cecilia Alves do Rego; Bertrand Bourre; Md Damien Biotti; Romain Marignier; Ana Martins Silva; Ernestina Santos; et al.. "Pregnancy in Patients With AQP4-Ab, MOG-Ab or Double-Negative Neuromyelitis Optica Disorder.". Neurology (2021): https://n.neurology.org/content/early/2021/02/24/WNL.0000000000011744.
    10.1212/wnl.0000000000011744
  13. Ana Martins Silva. "Limbic Encephalitis With Positivity for Anti-Flotillin Antibodies in Serum and CSF". Neurology: Clinical Practice 11 1 (2021): e8-e10. http://dx.doi.org/10.1212/cpj.0000000000000741.
    10.1212/cpj.0000000000000741
  14. Batista, Sónia; Martins da Silva, Ana; Sá, Maria José; Sousa, Lívia; Sá, João De; Pedrosa, Rui; Cerqueira, João; et al. "Recomendações Sobre a Abordagem da Esclerose Múltipla na Gravidez, Parto e Pós-Parto: Posição de Consenso do Grupo de Estudos de Esclerose Múltipla e da Sociedade Portuguesa de Obstetrícia e Medicina Materno-Fetal". Acta Médica Portuguesa 31 12 (2020): 785. http://dx.doi.org/10.20344/amp.12777.
    10.20344/amp.10752
  15. Floris, Alberto; Espinosa, Gerard; Serpa Pinto, Luisa; Kougkas, Nikolaos; Lo Monaco, Andrea; Lopalco, Giuseppe; Orlando, Ida; et al. "Discordance between patient and physician global assessment of disease activity in Behçet’s syndrome: a multicenter study cohort". Arthritis Research & Therapy 22 1 (2020): http://dx.doi.org/10.1186/s13075-020-02362-1.
    10.1186/s13075-020-02362-1
  16. da Silva, Ana Martins; Torres, C.; Ferreira, I.; Moreira, I.; Samões, R.; Sousa, A.P.; Santos, E.; Teixeira-Pinto, A.; Cavaco, S.. "Prognostic value of odor identification impairment in multiple sclerosis: 10-Years follow-up". Multiple Sclerosis and Related Disorders 46 (2020): 102486. http://dx.doi.org/10.1016/j.msard.2020.102486.
    10.1016/j.msard.2020.102486
  17. Batista, S.; Nunes, C. C.; Cerqueira, J. J.; Martins Silva, Ana; Correia de Sá, J.; Ferreira, J.; Mendonça, M. T.; et al. "REALMS study: real-world effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis in Portugal". Neurological Sciences (2020): http://dx.doi.org/10.1007/s10072-020-04726-6.
    10.1007/s10072-020-04726-6
  18. Ana Martins Silva; Ana Rita Castro; Paulo Pinho Costa. "O Papel da Disbiose na Esclerose Múltipla.". Sinapse 20 3 (2020): 121-133. https://doi.org/10.46531/ sinapse/ AR/200025/2020.
    Acesso aberto • Publicado
  19. Hauser, Stephen L.; Bar-Or, Amit; Cohen, Jeffrey A.; Comi, Giancarlo; Correale, Jorge; Coyle, Patricia K.; Cross, Anne H.; et al. "Ofatumumab versus Teriflunomide in Multiple Sclerosis". New England Journal of Medicine 383 6 (2020): 546-557. http://dx.doi.org/10.1056/nejmoa1917246.
    10.1056/nejmoa1917246
  20. Piga, Matteo; Floris, Alberto; Espinosa, Gerard; Serpa Pinto, Luísa; Kougkas, Nikolaos; Lo Monaco, Andrea; Lopalco, Giuseppe; et al. "Development and preliminary validation of the Behçet’s syndrome Overall Damage Index (BODI)". RMD Open 6 2 (2020): e001192. http://dx.doi.org/10.1136/rmdopen-2020-001192.
    10.1136/rmdopen-2020-001192
  21. Branco, Mariana; Alves, Ivânia; Martins da Silva, Ana; Pinheiro, Joaquim; Sá, Maria José; Correia, Inês; Sousa, Lívia; et al. "The epidemiology of multiple sclerosis in the entre Douro e Vouga region of northern Portugal: a multisource population-based study". BMC Neurology 20 1 (2020): http://dx.doi.org/10.1186/s12883-020-01755-8.
    10.1186/s12883-020-01755-8
  22. Sá, Maria; Nunes, Carla Cecília; da Silva, Ana Martins; Mota, Patrícia; Pinto-Marques, José. "JC virus antibodies in Portuguese multiple sclerosis patients: JUSTIFY study results". Journal of the Neurological Sciences 406 (2019): 116426. http://dx.doi.org/10.1016/j.jns.2019.116426.
    10.1016/j.jns.2019.116426
  23. Hupperts, Raymond; Smolders, Joost; Vieth, Reinhold; Holmøy, Trygve; Marhardt, Kurt; Schluep, Myriam; Killestein, Joep; et al. "Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon ß-1a". Neurology (2019): 10.1212/WNL.00000000. http://dx.doi.org/10.1212/wnl.0000000000008445.
    Publicado • 10.1212/wnl.0000000000008445 • Pessoal de suporte
  24. Ladeira, Filipa; Braz, Luís; Salgado, Paula; Vaz, Soraia; Leitão, Lia; Félix, Catarina; Correia, Ana Sofia; et al. "A multicenter, non-interventional study to evaluate the disease activity in Multiple Sclerosis after withdrawal of Natalizumab in Portugal". Clinical Neurology and Neurosurgery 184 (2019): 105390. http://dx.doi.org/10.1016/j.clineuro.2019.105390.
    10.1016/j.clineuro.2019.105390
  25. Ana Martins Silva. "ANTI-N-METHYL-D-ASPARTATE RECEPTOR ENCEPHALITIS IN PEDIATRIC AGE". Nascer e Crescer - Birth and Growth Medical Journal 28 2 (2019): 63-69.
    Publicado
  26. Gabriel, Denis; Duarte, Sara; Felgueiras, Rui; da Silva, Ana Martins; Santos, Ernestina. "Spontaneous remission lasting 3 decades in myelin oligodendrocyte glycoprotein disease". Neurology: Clinical Practice 9 6 (2019): 522-523. http://dx.doi.org/10.1212/cpj.0000000000000655.
    Publicado • 10.1212/cpj.0000000000000655
  27. Santos, Ernestina; Bettencourt, Andreia; Duarte, Sara; Gabriel, Denis; Oliveira, Vanessa; da Silva, Ana Martins; Costa, Paulo Pinho; et al. "Refractory myasthenia gravis: Characteristics of a portuguese cohort". Muscle & Nerve 60 2 (2019): 188-191. http://dx.doi.org/10.1002/mus.26507.
    10.1002/mus.26507
  28. Aires, Andreia; Barros, A; Machado, C; Fitas, D; Cação, G; Pedrosa, R; Cerqueira, J; Perdigão, S; Martins da Silva, A. "Diagnostic Delay of Multiple Sclerosis in a Portuguese Population.". Acta Médica Portuguesa 32 4 (2019): 289. https://doi.org/10.20344/amp.11187.
    Publicado • 10.20344/amp.11187
  29. Wolfe, Gil I; Kaminski, Henry J; Aban, Inmaculada B; Minisman, Greg; Kuo, Hui-Chien; Marx, Alexander; Ströbel, Philipp; et al. "Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial". The Lancet Neurology 18 3 (2019): 259-268. http://dx.doi.org/10.1016/s1474-4422(18)30392-2.
    10.1016/s1474-4422(18)30392-2
  30. Cação, Gonçalo; Calejo, Margarida; Alves, José Eduardo; Medeiros, Pedro Bettencourt; Vila-Cha, Nuno; Mendonça, Teresa; Taipa, Ricardo; Silva, Ana Martins; Damásio, Joana. "Clinical features of hypertrophic pachymeningitis in a center survey". Neurological Sciences 40 3 (2018): 543-551. http://dx.doi.org/10.1007/s10072-018-3689-3.
    10.1007/s10072-018-3689-3
  31. Santos, Ernestina; Silva, Ana Martins; Stroebel, Philipp; Marinho, Antonio; Willcox, Nick; Goncalves, Guilherme; Lopes, Carlos; Marx, Alexander; Leite, Maria Isabel. "Signs heralding appearance of thymomas after extended thymectomy for myasthenia gravis". Neurology: Clinical Practice 9 1 (2018): 48-52. http://dx.doi.org/10.1212/cpj.0000000000000551.
    10.1212/cpj.0000000000000551
  32. Pais Ribeiro, José Luís; Martins da Silva, Ana; Vilhena, Estela; Moreira, Inês; Santos, Ernestina; Mendonça, Denisa. "The hospital anxiety and depression scale, in patients with multiple sclerosis". Neuropsychiatric Disease and Treatment Volume 14 (2018): 3193-3197. http://dx.doi.org/10.2147/ndt.s184260.
    10.2147/ndt.s184260
  33. Bettencourt, Andreia; Boleixa, Daniela; Reguengo, Henrique; Samões, Raquel; Santos, Ernestina; Oliveira, José Carlos; Silva, Berta; Costa, Paulo Pinho; da Silva, Ana Martins. "Serum 25-hydroxyvitamin D levels in multiple sclerosis patients from the north of Portugal". The Journal of Steroid Biochemistry and Molecular Biology 180 (2018): 137-141. http://dx.doi.org/10.1016/j.jsbmb.2017.09.016.
    10.1016/j.jsbmb.2017.09.016
  34. Abreu, Pedro; Pedrosa, Rui; Sá, Maria José; Cerqueira, João; Sousa, Lívia; Da Silva, Ana Martins; Pinheiro, Joaquim; et al. "Recomendações e Consensos do Grupo de Estudos de Esclerose Múltipla e da Sociedade Portuguesa de Neurorradiologia sobre Ressonância Magnética na Esclerose Múltipla na Prática Clínica: Parte 1". Acta Médica Portuguesa 31 5 (2018): 281. http://dx.doi.org/10.20344/amp.10503.
    10.20344/amp.10503
  35. Monteiro, Cecilia; Martins da Silva, Ana; Ferreira, Natália; Mesgarzadeh, Jaleh; Novais, Marta; Coelho, Teresa; Kelly, Jeffery W.. "Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (p.TTRV50M) amyloidosis patients". Amyloid 25 2 (2018): 120-128. http://dx.doi.org/10.1080/13506129.2018.1479249.
    10.1080/13506129.2018.1479249
  36. Kappos, Ludwig; Bar-Or, Amit; Cree, Bruce A C; Fox, Robert J; Giovannoni, Gavin; Gold, Ralf; Vermersch, Patrick; et al. "Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study". The Lancet 391 10127 (2018): 1263-1273. http://dx.doi.org/10.1016/s0140-6736(18)30475-6.
    10.1016/s0140-6736(18)30475-6
  37. ernestina Santos; António Braga; Denis Gabriel; Sara Duarte; Ana Martins Silva; Ilda Matos; Marta Freijo; et al. "MuSK myasthenia gravis and pregnancy". Neuromuscular Disorders (2018): http://dx.doi.org/10.1016/j.nmd.2017.11.014.
    10.1016/j.nmd.2017.11.014
  38. Martins da Silva, Ana; Cavaco, Sara; Fernandes, Joana; Samões, Raquel; Alves, Cristina; Cardoso, Márcio; Kelly, Jeffery W.; Monteiro, Cecília; Coelho, Teresa. "Age-dependent cognitive dysfunction in untreated hereditary transthyretin amyloidosis". Journal of Neurology 265 2 (2017): 299-307. http://dx.doi.org/10.1007/s00415-017-8668-8.
    10.1007/s00415-017-8668-8
  39. Duarte, Sara; Santos, Ernestina; Martins, Joana; Martins Silva, Ana; Lopes, Carlos; Gonçalves, Guilherme; Leite, Maria Isabel. "Myasthenia gravis with systemic and neurological polyautoimmunity". Journal of the Neurological Sciences 381 (2017): 39-40. http://dx.doi.org/10.1016/j.jns.2017.08.010.
    10.1016/j.jns.2017.08.010
  40. Bettencourt, Andreia; Boleixa, Daniela; Guimarães, Ana Luísa; Leal, Bárbara; Carvalho, Cláudia; Brás, Sandra; Samões, Raquel; et al. "The vitamin D receptor gene FokI polymorphism and Multiple Sclerosis in a Northern Portuguese population". Journal of Neuroimmunology 309 (2017): 34-37. http://dx.doi.org/10.1016/j.jneuroim.2017.05.005.
    10.1016/j.jneuroim.2017.05.005
  41. Ernestina Santos; Andreia Bettencourt; Ana Martins Silva; Daniela Boleixa; Dina Lopes; Sandra Brás; Paulo Pinho e Costa; et al. "HLA and age of onset in myasthenia gravis". Neuromuscular Disorders (2017): http://dx.doi.org/10.1016/j.nmd.2017.04.002.
    10.1016/j.nmd.2017.04.002
  42. Santos E; Coutinho E; Martins da Silva A; Marinho A; Vasconcelos C; Taipa R; Pires MM; et al. "Inflammatory myopathy associated with myasthenia gravis with and without thymic pathology: Report of four cases and literature review.". (2017): http://europepmc.org/abstract/med/28414153.
    10.1016/j.autrev.2017.04.009
  43. Samões R; Taipa R; Valdrez K; Gonçalves I; Melo Pires M; Martins da Silva A; Coelho T. "Amyloid detection in the transverse carpal ligament of patients with hereditary ATTR V30M amyloidosis and carpal tunnel syndrome.". (2017): http://europepmc.org/abstract/med/28413892.
    10.1080/13506129.2017.1313222
  44. Cação G; Santos E; Martins Silva A. "Concurrent autoimmune hepatitis in multiple sclerosis.". (2017): http://europepmc.org/abstract/med/28273779.
    10.1177/1352458517692885
  45. Montalban, Xavier; Hauser, Stephen L.; Kappos, Ludwig; Arnold, Douglas L.; Bar-Or, Amit; Comi, Giancarlo; de Seze, Jérôme; et al. "Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis". New England Journal of Medicine 376 3 (2017): 209-220. http://dx.doi.org/10.1056/nejmoa1606468.
    10.1056/nejmoa1606468
  46. Bettencourt A; Boleixa D; Reis J; Oliveira JC; Mendonça D; Costa PP; Silva BMD; Marinho A; Silva AMD. "Serum 25-hydroxyvitamin D levels in a healthy population from the North of Portugal.". (2016): http://europepmc.org/abstract/med/27825978.
    10.1016/j.jsbmb.2016.11.005
  47. Santos E; Coutinho E; Moreira I; Silva AM; Lopes D; Costa H; Silveira F; et al. "Epidemiology of myasthenia gravis in Northern Portugal: Frequency estimates and clinical epidemiological distribution of cases.". (2016): http://europepmc.org/abstract/med/26851892.
    10.1002/mus.25068
  48. Macdonell R; Nagels G; Laplaud DA; Pozzilli C; de Jong B; Martins da Silva A; Nicholas R; et al. "Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine.". (2016): http://europepmc.org/abstract/med/26447066.
    10.1177/1352458515606809
  49. Nour MM; Nakashima I; Coutinho E; Woodhall M; Sousa F; Revis J; Takai Y; et al. "Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder.". (2016): http://europepmc.org/abstract/med/26581304.
    10.1212/wnl.0000000000002208
  50. Pruppers MH; Merkies IS; Faber CG; Da Silva AM; Costa V; Coelho T. "The Val30Met familial amyloid polyneuropathy specific Rasch-built overall disability scale (FAP-RODS(©) ).". (2015): http://europepmc.org/abstract/med/26115039.
    10.1111/jns.12120
  51. Marta M; Santos E; Coutinho E; Silva AM; Correia J; Vasconcelos C; Giovannoni G. "The role of infections in Behçet disease and neuro-Behçet syndrome.". (2015): http://europepmc.org/abstract/med/25769946.
    10.1016/j.autrev.2015.02.009
  52. Martins Da Silva A; Cavaco S; Moreira I; Bettencourt A; Santos E; Pinto C; Gonçalves A; et al. "Cognitive reserve in multiple sclerosis: Protective effects of education.". (2015): http://europepmc.org/abstract/med/25948624.
    10.1177/1352458515581874
  53. Moreira I; Teixeira F; Martins Silva A; Vasconcelos C; Farinha F; Santos E. "Frequent involvement of central nervous system in primary Sjogren syndrome.". (2015): http://europepmc.org/abstract/med/25056402.
    10.1007/s00296-014-3097-9
  54. Bettencourt A; Carvalho C; Leal B; Brás S; Lopes D; Martins da Silva A; Santos E; et al. "The Protective Role of HLA-DRB1(*)13 in Autoimmune Diseases.". (2015): http://europepmc.org/abstract/med/26605347.
    10.1155/2015/948723
  55. Domingos J; Ferrão C; Ramalho J; Rodrigues T; Moreira B; Santos E; Bettencourt A; et al. "Characteristics of Neuro-Behçet's Disease in a Case-Series from a Single Centre in Northern Portugal.". (2015): http://europepmc.org/abstract/med/25997636.
    10.1159/000381210
  56. Coelho T; da Silva AM; Alves C; Cardoso M; Monteiro C; Fonseca I; Rodrigues C; Costa V. "Familial Amyloid Polyneuropathy treatment with Tafamidis – evaluation of one- and two-year treatment in Porto, Portugal.". (2015): http://europepmc.org/abstract/PMC/PMC4642094.
    10.1186/1750-1172-10-s1-o25
  57. Hupperts R; Ghazi-Visser L; Martins Silva A; Arvanitis M; Kuusisto H; Marhardt K; Vlaikidis N; STAR Study Group. "The STAR Study: a real-world, international, observational study of the safety and tolerability of, and adherence to, serum-free subcutaneous interferon ß-1a in patients with relapsing multiple sclerosis.". (2014): http://europepmc.org/abstract/med/24811754.
    10.1016/j.clinthera.2014.04.002
  58. Sousa L; de Sa J; Sa MJ; Cerqueira JJ; Martins-Silva A; Portugal Experience with Natalizumab Study Group. "The efficacy and safety of natalizumab for the treatment of multiple sclerosis in Portugal: a retrospective study.". (2014): http://europepmc.org/abstract/med/25342053.
  59. Bettencourt A; Silva AM; Carvalho C; Leal B; Santos E; Costa PP; Silva BM. "The role of KIR2DS1 in multiple sclerosis--KIR in Portuguese MS patients.". (2014): http://europepmc.org/abstract/med/24529855.
    10.1016/j.jneuroim.2014.01.009
  60. Lemos C; Coelho T; Alves-Ferreira M; Martins-da-Silva A; Sequeiros J; Mendonça D; Sousa A. "Overcoming artefact: anticipation in 284 Portuguese kindreds with familial amyloid polyneuropathy (FAP) ATTRV30M.". (2014): http://europepmc.org/abstract/med/24046394.
    10.1136/jnnp-2013-305383
  61. da Silva AM; Santos ME; Portuguese JEMS Study Investigators. "JCV epidemiology in MS (JEMS)--epidemiology of anti-JCV antibody prevalence in multiple sclerosis patients--Portuguese data.". (2014): http://europepmc.org/abstract/med/24369270.
    10.1016/j.jns.2013.11.031
  62. Samões R; Carvalho S; Alves R; Torres T; Silva AM. "Ischemic skin necrosis caused by glatiramer acetate in multiple sclerosis patients.". (2014): http://europepmc.org/abstract/med/24751754.
    10.1684/ejd.2014.2349
  63. Bettencourt A; Leal B; Carvalho C; Oliveira R; Martins Silva A; Vaz Patto J; Bastos M; et al. "CC chemokine receptor polymorphism CCR5¿32 in Portuguese Behcet's disease patients.". (2014): http://europepmc.org/abstract/med/25268662.
  64. Coelho T; Maia LF; da Silva AM; Cruz MW; Planté-Bordeneuve V; Suhr OB; Conceiçao I; et al. "Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy.". (2013): http://europepmc.org/abstract/med/23974642.
    10.1007/s00415-013-7051-7
  65. Coelho T; Adams D; Silva A; Lozeron P; Hawkins PN; Mant T; Perez J; et al. "Safety and efficacy of RNAi therapy for transthyretin amyloidosis.". (2013): http://europepmc.org/abstract/med/23984729.
    10.1056/NEJMoa1208760
  66. Amato N; Riva N; Cursi M; Martins-Silva A; Martinelli V; Comola M; Fazio R; Comi G; Leocani L. "Different Frontal Involvement in ALS and PLS Revealed by Stroop Event-Related Potentials and Reaction Times.". (2013): http://europepmc.org/abstract/med/24376417.
    10.3389/fnagi.2013.00082
  67. Amato, Ninfa; Riva, Nilo; Cursi, Marco; Martins-Silva, Ana; Martinelli, Vittorio; Comola, Mauro; Fazio, Raffaella; Comi, Giancarlo; Leocani, Letizia. "Different Frontal Involvement in ALS and PLS Revealed by Stroop Event-Related Potentials and Reaction Times". Frontiers in Aging Neuroscience 5 (2013): http://dx.doi.org/10.3389/fnagi.2013.00082.
    10.3389/fnagi.2013.00082
  68. Brandão M; Damásio J; Marinho A; da Silva AM; Vasconcelos J; Neves E; Almeida I; Farinha F; Vasconcelos C. "Systemic lupus erythematosus, progressive multifocal leukoencephalopathy, and T-CD4+ lymphopenia.". (2012): http://europepmc.org/abstract/med/22674017.
    10.1007/s12016-012-8327-x
  69. Coelho T; Maia LF; Martins da Silva A; Waddington Cruz M; Planté-Bordeneuve V; Lozeron P; Suhr OB; et al. "Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.". (2012): http://europepmc.org/abstract/med/22843282.
    10.1212/WNL.0b013e3182661eb1
  70. Leite MI; Coutinho E; Lana-Peixoto M; Apostolos S; Waters P; Sato D; Melamud L; et al. "Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients.". (2012): http://europepmc.org/abstract/med/22551731.
    10.1212/WNL.0b013e31825644ff
  71. Gomes MJ; Martins da Silva A; Salinas J; Silva MC; Figueiredo A; Cavadas V; Coelho T. "Female sexual and pelvic floor muscles dysfunctions in familial amyloidotic polyneuropathy (FAP-Portuguese type).". (2012): http://europepmc.org/abstract/med/22619139.
  72. Silva AM; Santos E; Moreira I; Bettencourt A; Coutinho E; Gonçalves A; Pinto C; Montalban X; Cavaco S. "Olfactory dysfunction in multiple sclerosis: association with secondary progression.". (2012): http://europepmc.org/abstract/med/22020420.
    10.1177/1352458511427156
  73. Kim W; Kim SH; Nakashima I; Takai Y; Fujihara K; Leite MI; Kitley J; et al. "Influence of pregnancy on neuromyelitis optica spectrum disorder.". (2012): http://europepmc.org/abstract/med/22491862.
    10.1212/WNL.0b013e318250d812
  74. Cavaco S; Martins da Silva A; Santos E; Coutinho E; Marinho A; Moreira I; Gonçalves A; et al. "Are cognitive and olfactory dysfunctions in neuropsychiatric lupus erythematosus dependent on anxiety or depression?". (2012): http://europepmc.org/abstract/med/22382338.
    10.3899/jrheum.110574
  75. Grimaldi L; Barkhof F; Beelke M; Burton J; Holmoy T; Hupperts R; Killestein J; et al. "A Randomized Trial of High-Dose Vitamin D2 in Relapsing-remitting Multiple Sclerosis". Neurology (2012): http://dx.doi.org/10.1212/01.wnl.0000413180.13413.ce.
    10.1212/01.wnl.0000413180.13413.ce
  76. Bettencourt A; Martins da Silva A; Pinho E Costa P; Martins Silva B. "Molecular genetic studies of multiple sclerosis in the portuguese population.". (2012): http://europepmc.org/abstract/med/23079250.
  77. da Silva AA; dos Santos Cavaco SM; Taipa RJ; Pinto PR; Pires MJ. "Medulloblastoma and gliomatosis cerebri: rare brain tumors in multiple sclerosis patients.". (2011): http://europepmc.org/abstract/med/21234776.
    10.1007/s10072-010-0468-1
  78. Taipa R; da Silva AM; Santos E; Pinto PS; Melo-Pires M. "Gliomatosis cerebri diagnostic challenge: two case reports.". (2011): http://europepmc.org/abstract/med/21881469.
    10.1097/NRL.0b013e318217363e
  79. Damásio J; Ramos C; Valdemar L; da Silva AM; Magalhães M. "A coincidental case of young-onset Parkinson disease and multiple sclerosis.". (2011): http://europepmc.org/abstract/med/21881474.
    10.1097/NRL.0b013e318224ed84
  80. da Silva AM; Vilhena E; Lopes A; Santos E; Gonçalves MA; Pinto C; Moreira I; Mendonça D; Cavaco S. "Depression and anxiety in a Portuguese MS population: associations with physical disability and severity of disease.". (2011): http://europepmc.org/abstract/med/21497358.
    10.1016/j.jns.2011.03.042
  81. Bettencourt A; Silva AM; Santos E; Gomes S; Mendonça D; Costa PP; Faustino P; Silva BM. "HFE gene polymorphisms and severity in Portuguese patients with multiple sclerosis.". (2011): http://europepmc.org/abstract/med/20586792.
    10.1111/j.1468-1331.2010.03109.x
  82. Devonshire V; Lapierre Y; Macdonell R; Ramo-Tello C; Patti F; Fontoura P; Suchet L; et al. "The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis.". (2011): http://europepmc.org/abstract/med/20561039.
    10.1111/j.1468-1331.2010.03110.x
  83. Cavaco S; da Silva AM; Pinto P; Coutinho E; Santos E; Bettencourt A; Pinto C; et al. "Cognitive functioning in Behcet's disease.". (2009): http://europepmc.org/abstract/med/19758154.
    10.1111/j.1749-6632.2009.04670.x
  84. Silva AM; Bettencourt A; Pereira C; Santos E; Carvalho C; Mendonça D; Costa PP; Monteiro L; Martins B. "Protective role of the HLA-A*02 allele in Portuguese patients with multiple sclerosis.". (2009): http://europepmc.org/abstract/med/19482867.
    10.1177/1352458509104588
  85. Bettencourt A; Pereira C; Carvalho L; Carvalho C; Patto JV; Bastos M; Silva AM; et al. "New insights of HLA class I association to Behcet's disease in Portuguese patients.". (2008): http://europepmc.org/abstract/med/18627572.
    10.1111/j.1399-0039.2008.01087.x
  86. Silva AM; Pereira C; Bettencourt A; Carvalho C; Couto AR; Leite MI; Marta M; et al. "The role of HLA-DRB1 alleles on susceptibility and outcome of a Portuguese Multiple Sclerosis population.". (2007): http://europepmc.org/abstract/med/17412364.
    10.1016/j.jns.2007.02.033
  87. Games Collaborative Group; Ban M; Booth D; Heard R; Stewart G; Goris A; Vandenbroeck K; et al. "Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans.". (2006): http://europepmc.org/abstract/med/16934875.
    10.1016/j.jneuroim.2006.06.003
  88. Roxburgh RH; Seaman SR; Masterman T; Hensiek AE; Sawcer SJ; Vukusic S; Achiti I; et al. "Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.". (2005): http://europepmc.org/abstract/med/15824338.
    10.1212/01.WNL.0000156155.19270.F8
  89. Comi E; Annovazzi P; Silva AM; Cursi M; Blasi V; Cadioli M; Inuggi A; et al. "Visual evoked potentials may be recorded simultaneously with fMRI scanning: A validation study.". (2005): http://europepmc.org/abstract/med/15678479.
    10.1002/hbm.20087
  90. Da Silva AM; Rocha N; Pinto M; Alves V; Farinha F; Correia AP; Coelho T; Magalhães M. "Tremor as the first neurological manifestation of Sneddon's syndrome.". (2005): http://europepmc.org/abstract/med/15382213.
    10.1002/mds.20270
  91. Silva AM; Pires MM; Bastos Leite AJ; Honavar M; Mendes A; Correia M; Nora M; et al. "[A retrospective study of Creutzfeldt-Jakob disease in North of Portugal 1993-2002: demographic, clinical and neuropathological features].". Arquivos de neuro-psiquiatria (2003): http://europepmc.org/abstract/med/14762597.
    10.1590/s0004-282x2003000600012
  92. Martins Silva B; Thorlacius T; Benediktsson K; Pereira C; Fossdal R; Jonsson HH; Silva A; et al. "A whole genome association study in multiple sclerosis patients from north Portugal.". (2003): http://europepmc.org/abstract/med/14575927.
    10.1016/j.jneuroim.2003.08.024
Capítulo de livro
  1. Daniela Boleixa; Andreia Bettencourt; António Marinho; Ana Martins Silva; Cláudia Carvalho; Berta Martins da Silva; Carlos Vasconcelos. "Vitamin D". In Mosaic of Autoimmunity. Elsevier, 2019.
    Publicado
  2. Andreia Bettencourt; Ana Martins Silva. "Etiopatogenia da esclerose múltipla". In Livro 100 perguntas chave na esclerose múltipla, 26-32. Portugal: Permanyer, 2018.
    Publicado
  3. Ana Martins Silva. "Esclerose Múltipla na Gravidez". In Introdução à Esclerose Múltipla, 199-208. Portugal: Grupo de Estudos da Esclerose Múltipla. Biogen Idec., 2010.
    Publicado
Livro
  1. Ana Martins Silva; João Cerqueira; João de Sá; José Vale dos Santos; Lívia Diogo Sousa; Maria José Sá. Consenso Estratégico Nacional para a Esclerose Múltipla. Lisboa, Portugal: Edições Universidade Católica Editora. 2020.
    Publicado
Atividades

Apresentação oral de trabalho

Título da apresentação Nome do evento
Anfitrião (Local do evento)
2021/11/25 Evolução da Abordagem Terapêutica da Amiloidose Explorers – Tegsedi transformado o cenário da amiloidose ATTRv
PTC Farmacêutica do Brasil
2021/11/18 Cognition in MS patients
Bristol Myers Squibb
2021/11/12 Integração dos patient-reported outcomes na prática clinica
Biogen
2021/10/29 PAF – quando o puzzle faz sentido
Sobi (Portugal)
2021/10/29 Ponesimod - Um novo DMD oral de 1ª linha para o tratamento da esclerose múltipla
Janssen (Portugal)
2021/05/28 Tratamento de indução na Esclerose Múltipla
Sociedade Portuguesa de Neurologia (Portugal)
2021/03/22 Considerações para a escolha do ASO como opção terapêutica baseada em casos clínicos Explorers
PTC Farmacêutica do Brasil
2021/02/21 Neuro-Lupus: a problemática do envolvimento neurológico
Unidade de Imunologia Clinica do Centro Hospitalar Universitário do Porto (Porto, Portugal)
2021/01/15 Envolvimento neurológico das doenças sistémicas
Unidade de Imunologia Clinica do Centro Hospitalar Universitário do Porto (Porto, Portugal)
2020/11/25 hATTR a Portuguese Disease: a clinical case approach Lux hATTR Multidisciplinar symposium
Alnylam Pharmaceuticals (Luxemburgo)
2020/11/25 Advances in disease management and monitoring of hATTR Lux hATTR Multidisciplinar symposium
Alnylam Pharmaceuticals (Luxemburgo)
2020/10/23 Amiloidose ATTRh: importância de um diagnóstico e tratamento precoce Simposium do 8º Congresso da SPEDNM
Alnylam Pharmaceuticals (Portugal)
2020/10/16 A Evolução do Conceito NEDA e as suas limitações práticas Brainstorm summit 2020
Biogen Idec (Lisboa, Portugal)
2020/07/18 PAF: Como retardar a progressão da doença e melhorar a qualidade de vida dos doentes Simposium do XXIX Congresso Brasileiro de Neurologia
PTC Farmacêutica do Brasil
2020/06/23 Resultados do Ensemble plus Moving Foward – Ocrelizumab: Perfusão de curta duração
ROCHE (Portugal)
2020/01/16 Central Nervous system involvement hATTR EU Preceptorship
Sociedade Portuguesa de Estudos de Doenças Neuromusculares (Porto, Portugal)
2020/01/16 Neurological exam hATTR EU Preceptorship
Sociedade Portuguesa de Estudos de Doenças Neuromusculares (Porto, Portugal)
2019/12/13 MS treatment in patients planning a pregnancy BRAIN STORM SUMMIT & IMAGING NETWORK 2019
Biogen Idec (Lisboa, Portugal)
2019/12/13 Long-Term Safety: more than 130.000 patients treated Ocrelizumab in focus
ROCHE (Porto, Portugal)
2019/11/19 Brain Health - Time matters in MS 12th Young Fellowship Course Oporto
Sanofi-Genzyme (Porto, Portugal)
2019/11/15 Esclerose Múltipla: Da teoria à prática real Simposium Sanofi-Genzyme, Congresso de Neurologia
Sanofi-Genzyme (Coimbra, Portugal)
2019/11/14 Nova opção terapêutica: Inotersen Simposium "Atualizações em Polineuropatia Amiloidótica Familiar - PAF", Congresso de Neurologia
Akcea Therapeutics (Coimbra, Portugal)
2019/10/02 Imunomoduladores e infeção na Esclerose Múltipla 16º Encontro Nacional de Atualização em Infecciologia
Serviço de Infeciologia do Centro Hospitalar Universitário do Porto (Porto, Portugal)
2019/09/11 Espasticidade: porque os sintomas são a parte visível da doença para quem tem Esclerose Múltipla
Almirall (Porto, Portugal)
2019/06/14 Ocrelizumab: From Clinical Trials to Real World Experience Sharing Experience Meeting
ROCHE (Porto, Portugal)
2019/04/06 Biomarcadores: uma nova era na Esclerose Múltipla IV EMin
Biogen Idec (Porto, Portugal)
2019 A importância da Cognição no doente com EM Brain Network - immersive learning (e-learning)
Biogen Idec

Orientação

Título / Tema
Papel desempenhado 		Curso (Tipo)
Instituição / Organização
2020 - Atual Epidemiological characterization of TTR-FAP patients diagnosed in Unidade Corino de Andrade
Orientador de Ana do Carmo Ramalho Moreira Azevedo
 Ciências Médicas (Doutoramento)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2019 - Atual Neuropsychological assessment in Multiple Sclerosis: the preditive value of neurodegenerative vision-related measures
Orientador de Dália Maria Guedes Martins Meira
 Ciências Médicas (Doutoramento)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2018 - Atual Polineuropatia Desmielinizante Inflamatória Crónica: Caracterização clínico-laboratorial e avaliação da incapacidade e impacto funcional na prática clínica
Orientador de André Daniel Aires Fernandes
 Medicina (Mestrado)
Centro Hospitalar Universitário do Porto EPE, Portugal
2017 - Atual Glycans as novel immunomodulators in Idiopathic Inflammatory Myopathies
Coorientador de Ana Cristina Cerveira Campar Almeida
 Ciências Médicas (Doutoramento)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2017 - Atual Síndrome de Sjogren: quadro clínico e relação com as aquaporinas 4 e 5 e seus anticorpos
Coorientador de Mariana Brandão Marques Fernandes da Silva
 Ciências Médicas (Doutoramento)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2019/10 - 2020/07 MicroRNAs inflamatórios como Biomarcadores de Exacerbação na Esclerose Múltipla
Orientador de Daniela Neves Silva
 Bioquímica (Licenciatura/Bacharelato)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2019/09 - 2020/07 Valor Preditivo de um teste olfactivo na Esclerose Múltipla
Orientador de Maria Clara Torres Cunha Carvalho
 Medicina (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2019/09 - 2020/07 O papel da disbiose intestinal na Esclerose Múltipla
Orientador de Ana Rita Moreira de Castro
 Medicina (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2013 - 2017/12/13 Genetic susceptibility and immune dysfunction in Multiple Sclerosis
Coorientador de Andreia Manuela Teixeira Bettencourt Moreira
 Ciências Biomédicas (Doutoramento)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2012 - 2017 Internal doctor training in the specialization of Neurology
Orientador de Ana Raquel Samões
 Medicina (Curso de aperfeiçoamento / especialização)
Centro Hospitalar Universitário do Porto EPE, Portugal
2014/01/02 - 2014/03/30 Internal doctor training in the specialization of Physical Medicine and Rehabilitation
Orientador de Diogo Manuel Maia Couto Soares
 Medicina (Curso de aperfeiçoamento / especialização)
Centro Hospitalar Universitário do Porto EPE, Portugal
2013/07/01 - 2013/09/30 Internal doctor training in the specialization of Psychiatry
Orientador de Vítor Filipe Oliveira Gonçalves Pimenta
 Medicina (Curso de aperfeiçoamento / especialização)
Hospital de Magalhães Lemos EPE, Portugal
2006 - 2011 Internal doctor training in the specialization of Neurology
Orientador de Éster Coutinho
 Medicina (Curso de aperfeiçoamento / especialização)
Centro Hospitalar Universitário do Porto EPE, Portugal
2005 - 2006 Internal doctor training in the specialization of Neuroradiology
Orientador de Pedro Pinto
 Medicina (Curso de aperfeiçoamento / especialização)
Centro Hospitalar Universitário do Porto EPE, Portugal

Organização de evento

Nome do evento
Tipo de evento (Tipo de participação) 		Instituição / Organização
2021/12 - Atual Multiple Sclerosis Academy 2021-2022 (2022/12)
Outro (Membro da Comissão Científica)
 Advance Health Education, Portugal
2020/11 - 2021/01 Course: "Imunologia para Neurologistas" (2020/11 - 2021/01)
Outro (Coorganizador)
 Grupo de Estudos de Esclerose Múltipla, Portugal
2020/12/08 - 2020/12/08 XV ANEM Symposium - Commemoration of the National Day of Multiple Sclerosis Patients (2020/12/08 - 2020/12/08)
Conferência (Presidente da Comissão Organizadora)
 Centro Hospitalar Universitário do Porto EPE, Portugal
2020/06 - 2020/10 Course "Infecciologia para Neurologistas" (2020/06 - 2020/10)
Outro (Membro da Comissão Organizadora)
 Grupo de Estudos de Esclerose Múltipla, Portugal
2019/12 - 2019/12 XIV ANEM Symposium - Commemoration of the National Day of Multiple Sclerosis Patients (2019/12/08)
Conferência (Presidente da Comissão Organizadora)

Participação em evento

Descrição da atividade
Tipo de evento 		Nome do evento
Instituição / Organização
2021/10/28 - 2021/10/28 Session moderator: EP Desmielinizantes (EP013-EP018) Cognição e Demência (EP03-EP036)
Simpósio
Sociedade Portuguesa de Neurologia, Portugal
2021/10/13 - 2021/10/15 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Congresso
European Committee for Treatment and Research in Multiple Sclerosis, Suiça
2021/07/03 - 2021/07/03 Session moderator: Are we ready to cure MS ? – Prof Mancardi
Simpósio
Grupo de Estudos de Esclerose Múltipla, Portugal
2021/06/25 - 2021/06/26 Peripheral Nerve Society 2021
Conferência
Peripheral Nerve Society, Estados Unidos
2021/06/19 - 2021/06/22 Congress European Academy of Neurology
Congresso
European Academy of Neurology, Áustria
2021/04/17 - 2021/04/22 73rd Annual Meeting of the American Academy of Neurology
Congresso
American Academy of Neurology, Estados Unidos
2019/11/28 - 2019/11/30 Board Moderator: "How many sarcoidosis? The great imitator!"
Encontro
 Autoimmune disease international meeting
Centro Hospitalar Universitário do Porto EPE, Portugal
2019/09/11 - 2019/09/13 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and Annual Conference of Rehabilitation in MS
Congresso
 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and Annual Conference of Rehabilitation in MS
European Committee for Treatment and Research in Multiple Sclerosis, Suiça
2019/05/31 - 2019/06/01 Board Moderator: "Diáspora e Esclerose Múltipla"
Encontro
 Reunião da Primavera do Grupo de Estudos de Esclerose Múltipla
2019/04/10 - 2019/04/14 Board Moderator: Neuroimmunopsicology
Congresso
 CVI Congresso de Autoimunidade e XXV reunião Anual do NEDAI

Júri de grau académico

Tema
Tipo de participação 		Nome do candidato (Tipo de grau)
Instituição / Organização
2021/07 Gene Suppression Therapy in Hereditary Cerebellar Ataxias- a Systematic Review
Vogal
 Carolina Inácio dos Santos (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2021/07 Stroke Laterality: impact on the time to admission and acute treatment
Presidente do júri
 Maria Beatriz Rodrigues Lagarteira (Mestrado)
2021/07 Impacto do levante precoce pós-operatório na qualidade de vida dos doentes submetidos a drenagem de hematoma subdural crónico
Presidente do júri
 Miguel Eduardo Cruz Fidalgo (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2021/06 Efficacy of Vagus Nerve Stimulation and Ictael
Presidente do júri
 Malaquias Barreto Laczkovits (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2021/01/27 Exploring the role of astrocytes in the pathophysiology of multiple sclerosis
Vogal
 Sofia Pereira das Neves (Doutoramento)
Universidade do Minho, Portugal
2020/07 A associação entre fenómeno de Raynaud e enxaqueca: prevalência e preditores clínicos.
Arguente principal
 Raquel Ferreira de Oliveira (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2020/07 Epidemiologia e Abordagem dos Traumatismos Crânio-encefálicos em Países com Sistema Nacional de Saúde: Revisão Bibliográfica Epidemiologia e Abordagem dos Traumatismos Crânio-encefálicos em Países com Sistema Nacional de Saúde
Presidente do júri
 Alexandra Santos Machado (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2020/07 Comorbilidades Psiquiátricas na Epilepsia Temporal Mesial com Esclerose do Hipocampo
Presidente do júri
 João Diogo Pereira Barreira (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2020/07 Epilepsy and an convulsant therapy in glioblastoma prognosis
Presidente do júri
 Carolina Isabel Vieira Bastos Salgado Coutinho (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2019 Complicações da Ventilação Não Invasiva na Insuficiência Respiratória Aguda: Casuística de uma Unidade de Cuidados Intermédios e Protocolo de Abordagem
Presidente do júri
 Sara Alves Araujo (Mestrado)
Centro Hospitalar Universitário do Porto EPE, Portugal
2019 Perioperative Management of Diabetes Mellitus. A Review
Presidente do júri
 Mariana Moreira Azevedo (Mestrado)
2018/07 Hidrocefalia de pressão normal clínica e resposta à derivação ventriculoperitoneal
Presidente do júri
 Francisco de Campos Paiva Ferreira Silva (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2018/07 Agentes biológicos no tratamento da espondiloartrite axial: impacto na actividade da doença e na qualidade de vida dos doentes
Presidente do júri
 Susana Maria Cardoso Moreira (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2018/07 Prognóstico cirúrgico em epilepsia - retirada da medicação
Presidente do júri
 Rebeca Isabel Barreto Gomes (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2018/07 Efeitos do exercicio fisico na insuficiência cardiaca com fração de ejeção preservada
Presidente do júri
 Mariana Lima Bragança (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2018/07 Polineuropatia amiloidótica familiar: atingimento cardiovascular após transplante hepático
Presidente do júri
 Diana patricia Pereira Coelho (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2018/04/09 Myasthenia Gravis in the north of Portugal: epidemiological, clinical and serologicalstudy and immunopathology of the thymus
Arguente
 Maria Ernestina Azevedo Moreira dos Santos (Doutoramento)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2017/12/22 Neural correlates of theory of mind impairment in multiple sclerosis
Arguente
 Sónia Raquel Marques Batista (Doutoramento)
Hospitais da Universidade de Coimbra, Portugal
2017/07 O paradoxo nutricional - a coexistência de obesidade e desnutrição
Presidente do júri
 Ana Rita Rodrigues Teixeira (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2017/07 Variabilidade na prevalência da codificação da asma nos cuidados de saúde primários na região Norte - uma comparação com a diabetes
Presidente do júri
 Ricardo Jorge Neves dos Santos Teixeira Pinto (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2017/07 Revisão de glioblastomas multiformes operados no CHP entre 2010 e 2014: caracterização da amostra e estudos dos factores de prognóstico
Arguente
 Penélope Cristina Correia (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2017/07 Estudo retrospectivo e caracterização dos doentes operados a oligodendrogliomas no Centro Hospitalar do Porto de Janeiro de 2000 a Dezembro de 2010.
Arguente
 Andreia Sofia Dias Coutinho (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2015/12/21 Impact of mechanotransduction in the context of central nervous system diseases
Arguente
 Daniela Nogueira da Rocha Mar (Doutoramento)
Universidade do Porto Faculdade de Engenharia, Portugal
2010/07 Miopatia induzida por Estatinas
Arguente
 Renata de Paola Chequer (Outro)
Centro Hospitalar Universitário do Porto EPE, Portugal

Arbitragem científica em revista

Nome da revista (ISSN) Editora
2019 - Atual Multiple Sclerosis and Related Disorders (2211-0348) Elsevier
2012 - Atual Sinapse (2184-4240)

Curso / Disciplina lecionado

Disciplina Curso (Tipo) Instituição / Organização
2007/09 - Atual Clinical Neurosciences Medicina (Mestrado integrado) Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2007/09 - Atual Neurological Semiology Medicina (Mestrado integrado) Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2019/06 - 2019/10 Infectiology for Neurologists Medicina (Outros) Centro Hospitalar Universitário do Porto EPE, Portugal
2003 - 2006 Neurophysiology and Neuromuscular Physiology Instituto Politécnico de Saude do Norte Escola Superior de Saúde do Vale do Ave, Portugal
2004 - 2005 Neurophysiology of Communication Ciências da Fala e da Audição (Mestrado) Universidade de Aveiro, Portugal

Membro de comissão

Descrição da atividade
Tipo de participação 		Instituição / Organização
2021/09/01 - Atual Representative of Portuguese Society of Neurology as Institutional member on the EAN Scientific Panel of Neuroimmunology
Membro
 European Academy of Neurology, Áustria
2021 - Atual Principal Investigator of GAVOTTE: A phase IIIB multicentre, randomized, double-blind, controlled study to evaluated the efficacy, safety and pharmacokinetics of a higher dose of ocrelizumab in adults with primary progressive multiple sclerosis
Outro
2021 - Atual Principal Investigator of ENhance: A Study To Evaluate The Efficacy AnD Safety Of Fenebrutinib Compared With Teriflunomide In relapsing multiple sclerosis
Outro
2021 - Atual Principal Investigator of EVOLUTION: A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis
Outro
2021 - Atual Principal Investigator of FENtrepid: A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis
Membro
2020/10 - Atual Sub-investigator of CHAMPION5 (Protocol ALXN1210-MG-306) - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis
Outro
2020/06 - Atual Principal Investigator and National Cordenator of ORATORIO-HAND (Protocol WA40404) - A phase IIIb multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Ocrelizumab in assaults with primary progressive Multiple Sclerosis
Outro
2020 - Atual Sub-investigator of NEURO-TTRansform - A Study to Evaluate the Efficacy and Safety of AKCEA-TTR-LRx in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Membro
2020 - Atual Member of Scientific Committee of the working group in the area "Inflammatory and Demyelinating Diseases" of the Portuguese Society of Neurology
Membro
2020 - Atual Principal Investigator of ARTIOS and and National Coordinating Investigator: A phase 4 single arm, prospective, multicenter, open label study to evaluated ofatumumab treatment effectiveness and patient report outcomes in patients with relapsing multiple sclerosis transitioning from dimethyl fumarate or fingolimod therapy
Membro
2019/12 - Atual Sub-Investigator of Eidos AG10-301 – A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRIBUTE-CM Trial)
Outro
2019/04 - Atual Sub-Investigator of HELIOS-A – A Phase 3 Global, RANDOMIZED, OPEN-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
Outro
2019 - Atual Expert collaborating in the elaboration of the NOC on Prevention and Treatment of Vitamin D Deficiency
Membro
 Direção-Geral de Saúde, Portugal
2019 - Atual Principal Investigator of OPTIMUM-LT – Multicenter, Non-comparative Extension to Study AC-058B301, to Investigate the Long-term Safety, Tolerability, and Control of Disease of Ponesimod 20 mg in Subjects With Relapsing Multiple Sclerosis (Phase III Trial)
Outro
2019 - Atual Principal Investigator of ALITHIOS – An Open-label, Single Arm, Multi-center Extension Study Evaluating Long-term Safety, Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis (Phase III Trial)
Outro
2018/09 - Atual Principal Investigator and National Coordinating Investigator of CLARIFY – A 2-year Prospective Study to Assess Health-related Quality of Life in Subjects with Highly-active Relapsing Multiple Sclerosis Treated with Mavenclad® (Phase IV Trial)
Outro
2018/07 - Atual Principal Investigator of TeriLIVE-QoL Observational, non-interventional Portuguese study to assess quality of life in patients with Relapsing-Remitting Multiple Sclerosis treated with teriflunomide 14 mg in a real clinical setting (Phase IV Trial)
Outro
2018/01 - Atual Portuguese Representative of Multiple Sclerosis International Federation (IMSB)
Membro
2018 - Atual Principal Investigator of A Phase 1, open-label study of intravenous (IV) PRX004 as a single agent in subjects with hereditary amyloid transthyretin (hATTR) amyloidosis
Outro
2017/10 - Atual Principal Investigator of ENSEMBLE – An Open Label, single-arm study to evaluate the effectiveness and safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosis (Phase III Trial)
Outro
2014/05 - Atual Sub-Investigator of APOLLO – A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ALN-TTR02 in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy) (Phase III Trial)
Outro
2014 - Atual Principal Investigator of Protocol 109MS408 A multicenter, open-label study evaluating the effectiveness of oral tecfidera (Dimethyl Fumarate) on MS disease activity and patient-report outcomes in subjects with relapsing-remitting multiple sclerosis in the real-world setting (Protec) (Phase IV Trial)
Outro
2013/11 - Atual Principal Investigator of Protocol CBAF312A2304 – A multicenter, randomized, double blinded, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary multiple scleroris (Phase III Trial)
Outro
2013/11 - Atual Sub-Investigator of ALN-TTR02-003 – A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetis of ALN-TTR02 in Patients with Familial Amyloidotic Polyneuropathy Who have Previously Received ALN-TTR02 (Phase II Trial)
Outro
2013 - Atual Principal Investigator of PASSAGE Long-term, prospective, non-interventional, multinational and parallel cohort study that monitors safety in MS patients who have recently started treatment with Fingolimod, once daily, or treated with another approved disease-modifying therapy (TMD) (Phase IV Trial)
Outro
2013 - Atual Principal Investigator of GYLENIA Multinational registration of exposure to Gilenya during pregnancy in multiple sclerosis (Phase IV Trial)
Outro
2012/09 - Atual Sub-Investigator of A Phase 2, Open-Label, Multi-Dose, Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Infusions of ALN-TTR02 in Patients with TTR Amyloidosis (Phase II Trial)
Outro
2010/03 - Atual Member of Group Technical Validation Therapy and Good Clinical Practice in Multiple Sclerosis of General Health Directorate (DGS)
Membro
 Direção-Geral de Saúde, Portugal
2009 - Atual Scientific-technical adviser of the National Association of Multiple Sclerosis (ANEM)
Membro
2017/01 - 2021/10/01 Boarding Member of Grupo de Estudos de Esclerose Múltipla (GEEM)
Membro
2017/02 - 2021/01 Principal Investigator of ASCLEPIOS – A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis (Phase III Trial)
Outro
2015/12 - 2021 Sub-Investigator of ALN-TTR02-006 – A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients with Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Clinical Study with Patisiran (Phase III Trial)
Outro
2016 - 2020/01 Principal Investigator of OPTIMUM (Oral Ponesimod versus Teriflunomide In relapsing MUltiple sclerosis) – Multicenter, randomized, double-blind, parallel-group, active controlled, superiority study to compare the efficacy and safety of ponesimod to teriflunomide in subjects with relapsing multiple sclerosis (Phase III Trial)
Outro
2018/05 - 2020 Principal Investigator of PRX004-101 – A Phase 1, Open-label, Dose Escalation Study of Intravenous PRX004 in Subjects with Amyloid Transthyretin (ATTR) Amyloidosis (Phase I Trial)
Outro
2017 - 2020 Principal Investigator of PLENO – Open-Label, Randomized, 2 arm, Active Comparator Study to Evaluate Safety and Tolerability in Portuguese Patients with Relapsing Remitting Multiple Sclerosis (RRMS) Transitioning from Standard-of-Care Subcutaneous Interferon Therapy to Peginterferon Beta-1ª (PLEGRIDYTM) (Phase III Trial)
Outro
2015/04 - 2020 Sub-Investigator of ISIS 420915-CS3 – An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy (FAP) (Phase III Trial)
Outro
2013/07 - 2020 Sub-Investigator of ISIS 420915-CS2 – A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy (Phase II/III Trial)
Outro
2012/03 - 2018/12 Principal Investigator of ORATORIO A Phase III, multicenter, randomized, parallel-group, double-blinded, placebo-controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis WA25046 (Ocrelizumab, Roche) (Phase III Trial)
Outro
2016 - 2018 Sub-Investigator of IMPRESS The impact of depression in patients with Multiple Sclerosis who started treatment with interferon-concrete 1a IM (Avonex) (Phase IV Trial)
Outro
2015 - 2018 Principal Investigator of LIBERATE – A Multicenter, Multinational, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra® When Used In Routine Medical Practice (LIBERATE) (Phase IV Trial)
Outro
2015 - 2016 Principal Investigator of PROADHER Prospective observational study of adherence to therapy in patients with Relapsing-Remitting Multiple Sclerosis using Rebismart (Phase IV Trial)
Outro
2014 - 2016 Principal Investigator of JUSTIFY – Epidemiology and retropective assessment of the seroprevalence of JC vírus Antibody in the Portuguese Relapsing Remitting MS patient population (Phase IV Trial)
Outro
2013 - 2016 Principal Investigator of CogniPlus Prospective study to evaluate the association between physical activity and cognitive function in patients with Relapsing-Remitting Multiple Sclerosis undergoing Betaferon treatment® (Phase IV)
Outro
2013 - 2015 Member of the Multiple Sclerosis Working Group of National Pharmacy and Therapeutics Committee (INFARMED)
Membro
 Infarmed Autoridade Nacional do Medicamento e Produtos de Saúde IP, Portugal
2012/10 - 2015 Principal Investigator of SOLAR – A three-arm, randomized, double-blind, placebo-controlled, multicenter, phase II study to evaluate the efficacy of VIGANTOL® oil as add-on therapy in subjects with Relapsing-Remitting Multiple Sclerosis receiving treatment with 44µ tiw of Rebif® (Phase II Trial)
Outro
2008 - 2014 Principal Investigator of TYGRIS-ROW Observational, prospective, open, international multicenter study to assess the safety of TYSABRI® (NATALIZUMAB) in the treatment of Relapsing-Remitting Multiple Sclerosis (Phase IV Trial)
Outro
2012/06 - 2013/07 Principal Investigator and National Coordinating Investigator of A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, Followed by an Open-Label Treatment Period, to Assess the Effect of Fampridine-PR 10 mg Twice Daily on Improvement in Muscle Strength, Mobility, and Physical Fatigue in Multiple Sclerosis (Phase IV Trial)
Outro
2007 - 2013 Sub-Investigator of Safety and Efficacy of orally Fx-1006 in patients with familial amyloid polyneuropathy (FAP): a phase II/III, randomized, doulble blind , placebo controlled study (Phase II/III Trial)
Outro
2010/12 - 2011/04 Principal Investigator of A 4-month, open-label, multi-center study to explore tolerability and safety and health outcomes of FTY720 in patients with relapsing forms of multiple sclerosis - CFTY720D2316 (Phase IV Trial)
Outro
2010 - 2011 Sub-Investigator of A Phase 1, Randomized, Single-Blind, Placebo-Controlled, Dose Escalation Trial to Evaluated the Safety and tolerability of a single Dose of Intravenous ALN-TTR01 in Patients with TTR Amyloidosis (Phase IV Trial)
Outro
2006 - 2011 Principal Investigator of Global Adherence Project (GAP) Observational, international and multicenter study with the objective of evaluating the rate of adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (Phase IV Trial)
Outro
2010 - 2010 Principal Investigator of BEACON (Phase IV Trial)
Outro
2009 - 2010 Representative of the Portuguese Neurology Society on the panel of the European Federation Neurological Societies (EFNS)
Membro
2009 - 2010 Sub-Investigator of An Open-Label Extension of Study Fx-005 Evaluating Long-Term Safety and Clinical Outcomes of Fx-1006A in patients with Transthyretin Amyloid Polyneuropathy (Phase IV Trial)
Outro
2008 - 2008 Principal Investigator of START (Phase IV Trial)
Outro
2006 - 2008 MGTX – Tymectomy trial in non-thymatous myasthenia gravis patients receiving prednisolone (Phase III Trial)
Outro
2005 - 2007 Principal Investigator of Cogni MS. Observational Study to Assess Cognition in Patients with early Multiple Sclerosis Schering AG- (Phase IV Trial).
Outro
2001 - 2001 Sub-Investigator of CL3-04200-006-PRT (Phase IV Trial)
Outro

Outro júri / avaliação

Descrição da atividade Instituição / Organização
2020/11 - 2020/11 Jury element of the Prize "Professor António Flores", Neurology Congress
2020 - 2020 Jury element of the Prize "Esclerose Múltipla para internos", 4th edition EMin
Distinções

Prémio

2021 Prémio para melhor comunicação oral da Reunião de Primavera/Verão do Grupo de Estudos de Esclerose Múltipla 2021
Grupo de Estudos de Esclerose Múltipla, Portugal
2021 Prémio António Flores para o melhor e-poster do Congresso de Neurologia de 2021
Sociedade Portuguesa de Neurologia, Portugal
2019 Orlando Leitão
Sociedade Portuguesa de Neurologia, Portugal
2017 Orlando Leitão
2015 Best Oral Communication on the 3th International Porto Congress on MS
2012 Sollari Allegro
2011 Investigator Award on Neuropathies
2010 António Flores
2009 Investigator Award by the EFNS Scientist Panel on Genetics and Metabolic Disorders
2007 Clinical investigator Award on the meeting of the Portuguese Society of Human Genetics
2006 International Society for Behçet Disease Young Investigator
2001 Serono of Demyelinating Diseases
2001 Novartis of Neurology
2001 Serono of Neurology/Demyelinating Diseases
1996 Santa Casa da Misericórdia
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal